MDA 19 – 10 mg

Brand:
Cayman
CAS:
1048973-47-2
Storage:
-20
UN-No:
Non-Hazardous - /

MDA 19 is a selective agonist of the human peripheral cannabinoid (CB2) receptor, with an EC50 value for activation (63.4 nM) that is 14-fold lower than that for central cannabinoid (CB1) activation (EC50 = 867 nM).{18383} Surprisingly, it acts as an inverse agonist at the rat CB2 receptor in cell-based functional assays.{18533} MDA19 attenuates tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and in CB2+/+ mice but not in CB2-/- mice, indicating that CB2 receptors mediated the effects of MDA19.{18383,18533} These effects of MDA 19 are blocked by the selective CB2 antagonist AM630.{18383}  

 

Available on backorder

SKU: 10563 - 10 mg Category:

Description

A selective agonist of the CB2 receptor, with an EC50 value for CB2 activation (63.4 nM) that is 14-fold lower than that for CB1 activation (EC50 = 867 nM); dose-dependently reduces tactile allodynia in rats and in CB2+/+ mice but not in CB2-/- mice


Formal name: (2Z)-2-(1-hexyl-1,2-dihydro-2-oxo-3H-indol-3-ylidene)hydrazide, benzoic acid

Synonyms: 

Molecular weight: 349.4

CAS: 1048973-47-2

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Drugs of Abuse||Research Area|Forensic Chemistry & Toxicology|Cannabinoids|Synthetic Cannabinoids